BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Todd R. Golub, Nicolas D. Werbeck et al.|Nature Cancer|2024Cited by 28
Patients with Allan‐Herndon‐Dudley Syndrome (<scp>MCT8</scp> Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa TreatmentNina‐Maria Wilpert, Markus Schuelke, Angela Hewitt et al.|Movement Disorders|2025Cited by 4
ANJ810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Todd R. Golub, Guo Wei et al.|Research Square|2023Cited by 1
Abstract 506: ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor modelsUlrike Rauh, Todd R. Golub, Guo Wei et al.|Cancer Research|2023Cited by 1